Developed operation method for patient-drived orthotopic xenograft model of hepatocellular carcinoma.

Abstract

Background: Patient-derived xenograft(PDX) model is a biological organized platform and a patient substitute. Recent studies use the ectopic model for hepatocellular carcinoma(HCC) but this model don’t reflect likewise the tumor state of patient. For exact prognosis, it is need to establish patient-derived orthotopic xenograft(PDOX) mouse model of HCC using direct injection technique. Additionally, secretion of growth factor from bone marrow stem cells is promoted after partial hepatectomy. Based on former PDX research, we develop the new protocol using direct injection technique. Methods: From January 2015 to June 2016, consent about getting tumor pieces to the patient of HCC. The pieces is stored in RPMI1640 and moved from operation room to research room immediately. For PDOX, 8∼10weeks old NOD SCID and NSG male mouse is used. The tumor pieces cutted to the 1mm cube. For stop the bleeding, inferior vena cava is blocked using Bulldog Clamp and the cube is directly injected median lobe to 3 places randomly. After clear the Bulldog Clamp, a left lobe is removed using tie. After 3 months, the PDOX mouse is checked for cancer growth using MRI or PET-CT. Successful PDOX model is sacrificed and succeeded a generation to another Balb/C-nude male mouse. Results: The rate of success of PDOX model is about 10% respectively. Formed tumor is verified by H&E staining. Conclusion: Based on protocol established, further study plan is required for improving on the rate of success to establish PDOX model and clinical application.